pharmaphorum

JANUARY 21, 2022

Balancing the incentivisation of innovation against affordable access to revolutionary new medicines is an age-old conundrum in the biopharmaceutical industry. The outputs of the innovation process are proving prohibitively expensive for high-income countries, and way beyond the reach of low- and middle-income countries.”. WHO is OMI?

Insurance 52

Insurance Vaccines 52

pharmaphorum

AUGUST 28, 2020

The world is awash with data, and while retailers and TV subscription services have perfected the art of collection and curation, public health has been trailing behind. Prof Brownstein, who is also chief innovation officer at Boston Children’s Hospital, said: “COVID-19 has put a real focus on the inadequacies of public health.

Hospitals 71

Hospitals 71

pharmaphorum

AUGUST 18, 2022

million price tag attached to the therapy when it was first made available in Europe, and is also well above the proposed $2.1 The company said it would give a treatment guarantee with the product, offering to reimburse health insurers up to 80% of the cost if Zynteglo stops working in the two years after it is administered.

FDA 52

FDA Insurance 52